BRAF and melanoma: Furthermore, targeting the transcription factors GLI1/GLI2 (nuclear effectors of the Hh pathway) was able to reverse the treatment resistance of melanoma cells refractory to BRAF inhibitors and even prevent the acquisition of resistance to chemotherapy.